NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	psoriasis
Date of first enrollment	19/03/2010
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : AIN457 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigational material : Subcutaneously Administered

Outcome(s)

Primary Outcome	PASI 75 achievement(Time Frame: 12 weeks)
Secondary Outcome	IGA (Time Frame: 12 weeks)

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	-Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization -At randomization, moderate to severe psoriasis as defined by: -PASI score of 12 or greater and, -IGA score of 3 or greater and, -Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater At screening and randomization
Exclude criteria	-Forms of psoriasis other than chronic plaque-type -Drug-induced psoriasis at randomization -Ongoing use of prohibited psoriasis treatments / medications at randomization. Other protocol-defined inclusion/exclusion criteria may apply